WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406141

CAS#: 491833-30-8

Description: Genz-123346 is a potent and selective glucosylceramide synthase inhibitor with potential anticancer activity. Exposure of cells to Genz-123346 and to other GCS inhibitors at non-toxic concentrations can enhance the killing of tumor cells by cytotoxic anti-cancer agents. Genz-123346 and a few other GCS inhibitors are substrates for multi-drug resistance efflux pumps such as P-gp (ABCB1, gP-170). In cell lines selected to over-express P-gp or which endogenously express P-gp, chemosensitization by Genz-123346 was primarily due to the effects on P-gp function.

Price and Availability


USD 150
USD 750
USD 3950

USD 250
USD 1450
USD 5650

USD 450
USD 2250

Genz-123346, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 2g may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406141
Name: Genz-123346
CAS#: 491833-30-8
Chemical Formula: C24H38N2O4
Exact Mass: 418.28316
Molecular Weight: 418.57
Elemental Analysis: C, 68.87; H, 9.15; N, 6.69; O, 15.29

Synonym: Genz123346; Genz-123346; Genz 123346

IUPAC/Chemical Name: N-[(1R,2R)-1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]nonanamide


InChi Code: InChI=1S/C24H38N2O4/c1-2-3-4-5-6-7-10-23(27)25-20(18-26-13-8-9-14-26)24(28)19-11-12-21-22(17-19)30-16-15-29-21/h11-12,17,20,24,28H,2-10,13-16,18H2,1H3,(H,25,27)/t20-,24-/m1/s1


Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1: Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS. Glycosphingolipids and insulin resistance. Adv Exp Med Biol. 2011;721:99-119. doi: 10.1007/978-1-4614-0650-1_7. Review. PubMed PMID: 21910085.

2: Silberstein C, Lucero MS, Zotta E, Copeland DP, Lingyun L, Repetto HA, Ibarra C. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2. Pediatr Res. 2011 May;69(5 Pt 1):390-4. doi: 10.1203/PDR.0b013e318211dd57. PubMed PMID: 21270676.

3: Chai L, McLaren RP, Byrne A, Chuang WL, Huang Y, Dufault MR, Pacheco J, Madhiwalla S, Zhang X, Zhang M, Teicher BA, Carter K, Cheng SH, Leonard JP, Xiang Y, Vasconcelles M, Goldberg MA, Copeland DP, Klinger KW, Lillie J, Madden SL, Jiang YA. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int J Oncol. 2011 Mar;38(3):701-11. doi: 10.3892/ijo.2010.888. Epub 2010 Dec 24. PubMed PMID: 21186402.

4: Schrier RW, Levi M. Lipids and renal cystic disease. Nephrol Dial Transplant. 2010 Nov;25(11):3490-2. doi: 10.1093/ndt/gfq545. Epub 2010 Sep 2. PubMed PMID: 20813766.

5: Takiar V, Caplan MJ. Telling kidneys to cease and decyst. Nat Med. 2010 Jul;16(7):751-2. doi: 10.1038/nm0710-751. PubMed PMID: 20613749.

6: Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, Belenky A, Bukanov NO, Dackowski WR, Husson H, Russo RJ, Shayman JA, Ledbetter SR, Leonard JP, Ibraghimov-Beskrovnaya O. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010 Jul;16(7):788-92. doi: 10.1038/nm.2171. Epub 2010 Jun 20. PubMed PMID: 20562878.

7: Karman J, Tedstone JL, Gumlaw NK, Zhu Y, Yew N, Siegel C, Guo S, Siwkowski A, Ruzek M, Jiang C, Cheng SH. Reducing glycosphingolipid biosynthesis in airway cells partially ameliorates disease manifestations in a mouse model of asthma. Int Immunol. 2010 Jul;22(7):593-603. doi: 10.1093/intimm/dxq044. Epub 2010 May 24. PubMed PMID: 20497953.

8: Zhao H, Przybylska M, Wu IH, Zhang J, Maniatis P, Pacheco J, Piepenhagen P, Copeland D, Arbeeny C, Shayman JA, Aerts JM, Jiang C, Cheng SH, Yew NS. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology. 2009 Jul;50(1):85-93. doi: 10.1002/hep.22970. PubMed PMID: 19444873.

9: Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes. 2007 May;56(5):1210-8. PubMed PMID: 17470562.